XML 21 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Supplemental Balance Sheet Information
 9 Months Ended
Jul. 31, 2016
Supplemental Balance Sheet Information [Abstract]  
Supplemental Balance Sheet Information
SUPPLEMENTAL BALANCE SHEET INFORMATION
Inventories
Inventories consisted of the following:
 
July 31, 2016
 
October 31, 2015
 
$
 
$
Raw materials, packaging components and spare parts
179.2

 
160.2

Work-in-process
88.1

 
63.5

Finished goods
124.4

 
145.9

Balance, end of period
391.7

 
369.6


Accounts payable and accrued liabilities
The following is the breakdown of accounts payable and accrued liabilities:
 
July 31, 2016
 
October 31, 2015
 
$
 
$
Trade payables
244.0

 
289.2

Interest payable
34.8

 
36.2

Accrued salaries and related expenses
81.8

 
89.5

Customer deposits
6.6

 
7.3

Repositioning
3.3

 
22.9

Other accruals
7.8

 
16.7

Balance, end of period
378.3

 
461.8


Intangible assets
The following table summarizes gross carrying amounts, accumulated amortization, and accumulated impairments related to the Company's identifiable intangible assets as of July 31, 2016:
Definite-lived intangible assets
Gross carrying value
 
Accumulated amortization
 
Net carrying value
 
Weighted Average Useful Life (in Years)
 
$
 
$
 
$
 
 
Favorable agreements
1.0

 
(1.0
)
 
—

 
—

Trade names
1.6

 
(0.6
)
 
1.0

 
5.6

Developed technology
54.1

 
(15.5
)
 
38.6

 
10.8

Trade secrets and patents
2.5

 
(0.2
)
 
2.3

 
14.5

Customer relationships
248.8

 
(35.7
)
 
213.1

 
14.2

Non-compete agreements
2.6

 
(1.5
)
 
1.1

 
3.0

Subtotal
310.6

 
(54.5
)
 
256.1

 
 
Foreign exchange
 
 
 
 
(3.3
)
 
 
Balance, end of period
 
 
 
 
252.8

 
 


Indefinite-lived intangible assets
Gross carrying value
 
Accumulated impairment
 
Net carrying value
 
$
 
$
 
$
In-process research and development
2.2

 
(0.9
)
 
1.3

Regulatory permits
0.2

 
—

 
0.2

Subtotal
2.4

 
(0.9
)
 
1.5

Foreign exchange
 
 
 
 
(0.2
)
Balance, end of period
 
 
 
 
1.3


In-process research and development (“IPR&D”) is classified as definite-lived or indefinite-lived depending on whether the product has been approved and if commercialization has begun. IPR&D for products that have been approved is classified as a definite-lived intangible asset and is amortized over the life of the asset. IPR&D for products that have not been approved is classified as an indefinite-lived intangible asset and either begins to be amortized upon approval and product commercialization or is written-off if the product is not approved.
In the first quarter of fiscal 2016, the Company sold an IPR&D asset to Banner Life Sciences for cash consideration equal to its net carrying value of $3.6 million. At the time of the sale, the asset had a gross carrying value of $7.9 million and had incurred $4.3 million in impairments.
Goodwill
The following table summarizes the changes in the carrying amount of goodwill for the nine months ended July 31, 2016:
 
Total
 
$
Balance at October 31, 2015 (1)
284.4

Measurement period adjustment (2)
(2.9
)
Foreign currency translation adjustments
0.3

Balance at July 31, 2016
281.8


(1) The opening cumulative goodwill balance is reflective of historical impairment charges of the full value of goodwill, which includes a $172.5 million impairment related to Puerto Rico operations, a $0.1 million impairment related to the Banner Canada operations, a $1.3 million impairment related to the Biosolutions business, a disposition impact on the sale of Banner Mexico of $3.1 million and a spinoff impact on the spinoff of Banner Life Sciences of $11.1 million.
(2) Represents a measurement period adjustment on the Irix Acquisition in the second quarter of fiscal 2016.